These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15672489)

  • 1. Growth-factor inhibition as therapy for Kaposi's sarcoma.
    Senior K
    Lancet Oncol; 2005 Jan; 6(1):7. PubMed ID: 15672489
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
    Koon HB; Bubley GJ; Pantanowitz L; Masiello D; Smith B; Crosby K; Proper J; Weeden W; Miller TE; Chatis P; Egorin MJ; Tahan SR; Dezube BJ
    J Clin Oncol; 2005 Feb; 23(5):982-9. PubMed ID: 15572730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042.
    Koon HB; Krown SE; Lee JY; Honda K; Rapisuwon S; Wang Z; Aboulafia D; Reid EG; Rudek MA; Dezube BJ; Noy A
    J Clin Oncol; 2014 Feb; 32(5):402-8. PubMed ID: 24378417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional genomics and the development of pathogenesis-targeted therapies for Kaposi's sarcoma.
    McAllister SC; Früh K; Moses AV
    Pharmacogenomics; 2005 Apr; 6(3):235-44. PubMed ID: 16013955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate in combination with other chemotherapeutic agents for chronic myelogenous leukemia.
    Tauchi T; Ohyashiki K
    Int J Hematol; 2004 Jun; 79(5):434-40. PubMed ID: 15239392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuing imatinib in chronic myeloid leukemia: don't try this at home.
    Mattison R; Larson RA
    Leuk Lymphoma; 2009 Jun; 50(6):868-70. PubMed ID: 19455466
    [No Abstract]   [Full Text] [Related]  

  • 7. Leukemia. Q&A highlights.
    Frame D; Sessions J; Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S22. PubMed ID: 18056929
    [No Abstract]   [Full Text] [Related]  

  • 8. KIT and PDGF as targets.
    Verweij J
    Cancer Treat Res; 2004; 120():117-27. PubMed ID: 15217221
    [No Abstract]   [Full Text] [Related]  

  • 9. Molecularly targeted therapy for Kaposi's sarcoma in a kidney transplant patient: case report, "what worked and what did not".
    Volkow P; Zinser JW; Correa-Rotter R
    BMC Nephrol; 2007 Mar; 8():6. PubMed ID: 17386117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension.
    Patterson KC; Weissmann A; Ahmadi T; Farber HW
    Ann Intern Med; 2006 Jul; 145(2):152-3. PubMed ID: 16847299
    [No Abstract]   [Full Text] [Related]  

  • 11. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
    Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
    Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful PDGFR-{alpha}/{beta} targeting with imatinib in uterine sarcoma.
    Trojan A; Montemurro M; Kamel M; Kristiansen G
    Ann Oncol; 2009 Nov; 20(11):1898-9. PubMed ID: 19748901
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeting mutant kinases in gastrointestinal stromal tumors: a paradigm for molecular therapy of other sarcomas.
    Heinrich MC; Corless CL
    Cancer Treat Res; 2004; 120():129-50. PubMed ID: 15217222
    [No Abstract]   [Full Text] [Related]  

  • 14. From bedside to bench: treatment for rare blood disorder yields clues to disease mechanism.
    Friedrich MJ
    J Natl Cancer Inst; 2003 Aug; 95(15):1102-3. PubMed ID: 12902432
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful delivery after planned discontinuation of imatinib in a patient with chronic myeloid leukemia.
    Kobayashi K; Takebayashi C; Miyata S; Narimatsu H; Kami M
    Intern Med; 2009; 48(5):369-71. PubMed ID: 19252364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis.
    Jung AG; Horny HP; Sotlar K; Overbeck T; Schön MP; Lippert U
    J Am Acad Dermatol; 2011 Jul; 65(1):224-6. PubMed ID: 21679828
    [No Abstract]   [Full Text] [Related]  

  • 17. Imatinib mesylate--a new oral targeted therapy.
    Savage DG; Antman KH
    N Engl J Med; 2002 Feb; 346(9):683-93. PubMed ID: 11870247
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical trials.
    Keill R
    Bull Am Coll Surg; 2003 May; 88(5):43. PubMed ID: 23581062
    [No Abstract]   [Full Text] [Related]  

  • 19. Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor.
    Sawyers CL
    J Clin Oncol; 2002 Sep; 20(17):3568-9. PubMed ID: 12202652
    [No Abstract]   [Full Text] [Related]  

  • 20. Weekly imatinib dosage for chronic eosinophilic leukaemia expressing FIP1L1-PDGFRA fusion transcript: extended follow-up.
    Helbig G; Moskwa A; Swiderska A; Urbanowicz A; Całbecka M; Gajkowska J; Zdziarska B; Brzeźniakiewicz K; Pogrzeba J; Krzemień S
    Br J Haematol; 2009 Apr; 145(1):132-4. PubMed ID: 19120352
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.